ERRATA

Following is a list of errata and corrections to *USP–NF*. The page number indicates where the item is found and in which official or pending official publication of *USP–NF*. If necessary, this list will be updated with every issue of *PF*. This information will also be available as a cumulative table in future *Supplements* and will appear in its corrected form in a future annual edition of *USP–NF*. Errata are considered to be items erroneously published that have not received the approval of the Council of Experts and that do not reflect the official requirement. USP staff is available to respond to questions regarding the accuracy of a particular requirement by calling 1-800-822-USPC.

***USP32–NF27* Page**	**Title**	**Section**	**Description**
900	*Description and Solubility*	*Citalopram Hydrobromide*	Line 2: Change ''Freely soluble in water, in alcohol, and in chloroform.'' to: Soluble in alcohol and sparingly soluble in water.
969	*Calcium and Vitamin D with Minerals Tablets*	*Assay for copper*	Line 3 under *Assay preparation*: Replace ''Proceed as directed for *Assay preparation* in the *Assay for calcium* under *Calcium with Vitamin D Tablets*, except to prepare the *Assay preparation* to contain 2 μg of copper per mL and to omit the use of the *Lanthanum chloride solution*.'' with: Heat for 6 to 12 hours in a muffle furnace maintained at about 550°, and cool. Add about 15 mL of hydrochloric acid, and boil gently on a hot plate or a steam bath for about 30 minutes, intermittently rinsing the inner surface of the crucible with 6 N hydrochloric acid. Cool, and quantitatively transfer the contents of the crucible to a 100-mL volumetric flask, rinsing the crucible with portions of 6 N hydrochloric acid. Dilute the contents of the flask with water to volume, mix, and filter, discarding the first 5 mL of the filtrate. Dilute the filtrate quantitatively, and stepwise if necessary, with 0.125 N hydrochloric acid to obtain a solution having a concentration of about 2 μg of copper per mL.
		Assay for manganese	Line 4 under *Assay preparation*: Replace ''Proceed as directed for *Assay preparation* in the *Assay for calcium* under *Calcium with Vitamin D Tablets*, except to prepare the *Assay preparation* to contain 1 μg of manganese per mL and to omit the use of the *Lanthanum chloride solution*.'' with: Heat for 6 to 12 hours in a muffle furnace maintained at about 550°, and cool. Add about 15 mL of hydrochloric acid, and boil gently on a hot plate or a steam bath for about 30 minutes, intermittently rinsing the inner surface of the crucible with 6 N hydrochloric acid. Cool, and quantitatively transfer the contents of the crucible to a 100-mL volumetric flask, rinsing the crucible with portions of 6 N hydrochloric acid. Dilute the contents of the flask with water to volume, mix, and filter, discarding the first 5 mL of the filtrate. Dilute the filtrate quantitatively, and stepwise if necessary, with 0.125 N hydrochloric acid to obtain a solution having a concentration of about 1 μg of manganese per mL.

© 2009 The United States Pharmacopeial Convention *All Rights Reserved.*

***USP32–NF27* Page**	**Title**	**Section**	**Description**
		Assay for zinc	Line 3 under *Assay preparation*: Replace ''Proceed as directed for *Assay preparation* in the *Assay for calcium* under *Calcium with Vitamin D Tablets*, except to prepare the *Assay preparation* to contain 2 μg of zinc per mL and to omit the use of the *Lanthanum chloride solution*.'' with: Heat for 6 to 12 hours in a muffle furnace maintained at about 550°, and cool. Add about 15 mL of hydrochloric acid, and boil gently on a hot plate or a steam bath for about 30 minutes, intermittently rinsing the inner surface of the crucible with 6 N hydrochloric acid. Cool, and quantitatively transfer the contents of the crucible to a 100-mL volumetric flask, rinsing the crucible with portions of 6 N hydrochloric acid. Dilute the contents of the flask with water to volume, mix, and filter, discarding the first 5 mL of the filtrate. Dilute the filtrate quantitatively, and stepwise if necessary, with 0.125 N hydrochloric acid to obtain a solution having a concentration of about 2 μg of zinc per mL.
1069	*Saw Palmetto*	*Content of fatty acids*	Line 17 under *Procedure*: Change ''0.5% of linolenic acid,'' to: 0.05% of linolenic acid,
1620	*Bacitracin*	*Composition*	Line 3 under *Peak identification solution*: Change ''sodium edetate (pH adjusted to 7.0'' to: edetate disodium (pH adjusted to 7.0
1623	*Bacitracin Zinc*	*Composition*	Line 1 under *Diluent*: Change ''Dissolve 40 g of sodium edetate'' to: Dissolve 40 g of edetate disodium
1807	*Carprofen Tablets*	*Chromatographic purity*	Line 6 under *Procedure*: Change ''in which C_S is the concentration, in mg per mL,'' to: in which C_S is the concentration, in μg per mL,
1845	*Cefotaxime for Injection*	*Uniformity of dosage units*	Line 1: Change ''**Uniformity of dosage units** ⟨905⟩— *Procedure*—Perform the *Assay* on individual containers using *Assay preparation 2, Assay preparation 3,* or *Assay preparation 4*, as appropriate.'' to: **Uniformity of dosage units** ⟨905⟩—meets the requirements.
2352	*Fenofibrate Capsules*	*Assay*	Line 1 under *Buffer solution pH 2.9*: Change ''Dissolve 136 g'' to: Dissolve 136 mg
2434	*Fluticasone Propionate*	*Limit of acetone*	Line 3 under *Chromatographic system*: Change the specified column from ''G15.'' to: G16.
3139	*Ondansetron Hydrochloride Oral Suspension*	*Definition*	Row 2 in the table: Change ''Vehicle: a mixture of Vehicle for Oral Suspension, (regular or sugar-free), *NF*, and Vehicle for Oral Solution, *NF* (1:1),'' to: Vehicle: a mixture of Vehicle for Oral Suspension, *NF* and Vehicle for Oral Solution (regular or sugar-free), *NF* (1:1),
3871	*Sterile Water for Irrigation*	*Bacterial endotoxins* ⟨85⟩	Line 1: Change ''not more than 0.25 Endotoxin Unit per mL.'' to: It contains less than 0.25 USP Endotoxin Unit per mL.

© 2009 The United States Pharmacopeial Convention *All Rights Reserved.*

***USP32–NF27* Page**	**Title**	**Section**	**Description**
First Supplement to USP32–NF27			
3924	⟨11⟩ *USP Reference Standards*	*USP Estradiol Related Compound B RS*	*USP Estradiol Related Compound B RS*, along with *USP Estradiol Related Compound C RS*, was intended to be published in the *First Supplement to USP32–NF27*, but did not appear. *USP Estradiol Related Compound B RS* is now being added to the *First Supplement to USP 32–NF 27*.
4059	*Fosinopril Sodium*	*Related Compounds*	*Table 1, Relative Retention Time* for *Impurity 1*, under TEST 1: Change ''0.12'' to: 0.53 *Table 1, Relative Retention Time* for *Impurity 2*, under TEST 1: Change ''0.24'' to: 0.67

© 2009 The United States Pharmacopeial Convention *All Rights Reserved.*